Project Grant R16AI201146
Award Date 8/6/26
Completion Date 7/31/30
Dollars Obligated $190K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Brooklyn Heights, NY 11201, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine a project grant of $100,228 on December 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the role of Plasmodium-specific cytolytic CD4+ T cells in malaria immunity. The research defines epitope specificity of expanded T cell clones from clinically immune individuals, characterizes the phenotype and function of ZEB2+ CD4+ T cells upon...
- The National Institute of Allergy and Infectious Diseases awarded $571,747 to Tulane University on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate alpha-satellite RNAs in Epstein-Barr virus lytic replication. The funded research examines how Epstein-Barr virus induces alpha-satellite RNAs—transcripts from tandem repetitive non-coding DNA sequences constituting 3–5% of the human genome—during viral lytic replication. The work explores the...
- The National Institute of Allergy and Infectious Diseases awarded Hennepin Healthcare Research Institute $661,037 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate an interleukin-15 (IL-15) cytokine-based therapy intended to enhance T and B cell immune responses to Plasmodium parasites and improve malaria vaccine efficacy. The research uses novel peptide-MHC class II and B cell tetramers in experimental Plasmodium infection and vaccination...
- The National Institute of Allergy and Infectious Diseases awarded the Research Foundation of The City University of New York $235,500 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the gut microbiome-sphingosine 1-phosphate (S1P) axis as a modulator of severe malaria. The research will use murine models to determine the effect of gut microbiota composition on intestinal S1P levels and malaria outcomes, identify gut bacteria involved in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Health Science Center at San Antonio $153,560 on October 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate disruption of the Epstein-Barr virus ribonucleotide reductase and APOBEC3B interaction as a therapeutic approach to restore natural antiviral immunity against EBV. The research addresses the absence of FDA-approved antivirals for EBV infection and the...
- The National Institute of Allergy and Infectious Diseases, operating under the Department of Health and Human Services, awarded Brigham & Women's Hospital Inc. (Department of Faulkner Pathology) $879,282 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research characterizing novel receptors for Epstein-Barr virus epithelial cell entry. The project identifies and investigates DSC2/3 receptors discovered through genome-wide CRISPR...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $778,827 on May 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize Epstein-Barr virus (EBV)-infected B cells in patients with multiple sclerosis. The research applies an innovative technology pipeline called ELUCIDATE (EBER-Labeled Unique Cell Identification and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $224,368 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors essential for Epstein-Barr virus episome persistence. The research targets mechanisms by which EBV maintains lifelong infection in humans and contributes to infectious mononucleosis, nasopharyngeal carcinoma, oral hairy leukoplakia, post-transplantation...
- The National Institute of Allergy and Infectious Diseases awarded New York University $466,125 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of perivascular macrophages in controlling neuroinflammatory disease severity. The research examines how border-associated macrophages (BAM), a resident population in the central nervous system perivascular space, contribute to blood-brain barrier function and limit inflammatory cell...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $247,500 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI193282). The award funds deep phenotyping of DR15-restricted CD4+ T cells specific for Epstein-Barr virus epitopes in cerebrospinal fluid and blood samples from people with multiple sclerosis. The research aims to understand how Epstein-Barr virus...